June 2025 - Corcept Therapeutics

Treatment of Hypercortisolism in People with Difficult-to-Control Type 2 Diabetes—Final Results of the CATALYST Trial

June 23, 2025

Pratley, DeFronzo, Aroda, Fonseca, Buse • 2025 • ADA

Comparative Effectiveness of Nab-Paclitaxel and Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (COMPASS)

June 20, 2025

Shahin et al. • 2025 • ESMO Gyn

Phase 3 Results of Relacorilant + Nab-Paclitaxel v Nab-Paclitaxel In Platinum-Resistant Ovarian Cancer (ROSELLA): Secondary Endpoints

June 19, 2025

Lorusso et al. • 2025 • ESMO Gyn

Impact of Relacorilant on Blood Pressure and Antihypertensive Medication Burden in Patients With Hypercortisolism and Hypertension: Results From the GRACE Study

June 9, 2025

Moraitis et al. • 2025 • Heart in Diabetes 2025

The Design of MOMENTUM: A Prospective Study of the Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension

June 9, 2025

Plutzky et al. • 2025 • Heart in Diabetes 2025

High Medication and Cardiovascular Disease Burden in Individuals With Difficult-to-Control Type 2 Diabetes: Clinical Characteristics From the CATALYST Study

June 9, 2025

DeFronzo et al. • 2025 • Heart in Diabetes 2025

DAZALS: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Of Dazucorilant, A Selective Glucocorticoid Receptor Modulator, In Amyotrophic Lateral Sclerosis

June 5, 2025

van den Berg et al. • 2025 • ENCALS 2025 Congress

ROSELLA: A Phase 3 Study of Relacorilant in Combination with Nab-Paclitaxel versus Nab-Paclitaxel Monotherapy in Patients with Platinum-Resistant Ovarian Cancer

June 2, 2025

A. Olawaiye et al. • 2025 •